Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2011-11-16

FDA Approved: EOVIST — Supplemental Application (Bayer HealthCare Pharmaceuticals Inc.)

View source ↗

Summary

FDA approves a supplemental application for EOVIST (gadoxetate disodium) from Bayer HealthCare Pharmaceuticals Inc. for its liver-imaging indication.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • EOVIST (GADOXETATE DISODIUM)

Snippet

SUPPL AP for EOVIST (GADOXETATE DISODIUM)